Clinical trials: Cancer, Hepatocellular
Hepatocellular Carcinoma
TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.
The TheraSphere Post-Approval Study is a post-market, prospective, single-arm, open-label, observational study to support the use of TheraSphere for the treatment of hepatocellular carcinoma (HCC).
- Trial name
- NCT05233098
- Testing
- Technetium-99m macroaggregated albumin (Tc-99m MAA)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Boston Scientific Corporation
Hepatocellular Carcinoma
11C-acetate for Treatment Response After Radiotherapy for HCC
It is thought that PET of the abdomen with 11C Acetate will provide new information regarding whether or not patient's have benefited from radiotherapy.
- Trial name
- NCT02549755
- Testing
- 11C-Acetate
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Justin Sims